Will cancer ever be cured — or are we just managing symptoms?

In this visionary episode, Dr. Dino Prato, founder of Envita Medical Centers, explores whether cancer can disappear — not just through early detection or conventional care, but by addressing root causes and using thousands of biological data points to map precise, targeted treatment plans.

🎯 What You’ll Learn:

• Why standard cancer care often uses just 24 data points to guide treatment
• How precision oncology uses DNA, RNA, immune profiling & spatial biology
• The connection between mitochondrial dysfunction, infections, toxins, and cancer
• How liquid biopsy and non-invasive detection may stop cancer early — or before it starts
• Why many standard treatments create resistance, and what alternatives offer fewer side effects
• How to track remission using circulating tumor DNA (ctDNA) and methylation scores — not just scans

📊 According to Envita’s 2024 published data, patients treated with precision targeting showed 35x better outcomes, 43x improved quality of life, and 95x fewer side effects compared to historical norms.*
*(See Outcomes Disclaimer Below)

“Cancer may be complex — but it’s not unbeatable when your plan is precise.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493